Phantom Neuro Secures Breakthrough Device and TAP Designations, Strengthening Its Leadership in Neurotechnology

Phantom Neuro has received two significant designations from the United States Food and Drug Administration (FDA). 

The company has been granted both the Breakthrough Device Designation and the highly selective Targeted Acceleration Pathway (TAP) Designation for its Phantom X platform, a minimally invasive neural interface. 

These designations support Phantom Neuro’s goal of enhancing human capability by enabling complex electronic systems, such as prosthetic limbs, to function as natural extensions of the body.

The Breakthrough Device Designation acknowledges the potential of Phantom Neuro’s technology to offer notable benefits over existing solutions for individuals with functional impairments. 

The TAP Designation, a selective recognition within the FDA’s Medical Device Accelerator programme, allows for early and structured engagement with the regulatory body, thereby expediting the pathway to market approval. 

With these designations, the company aims to accelerate its development and regulatory review, ultimately bringing its technology to patients more quickly and improving clinical outcomes.

Phantom X is designed to provide intuitive control over prosthetics and robotic devices through a neural interface that is implanted just beneath the skin. 

The procedure is straightforward and can be performed on an outpatient basis, making it accessible to a large number of surgeons across the United States. 

The system employs advanced algorithms to interpret natural human movements, delivering a seamless and lifelike experience in controlling prosthetic limbs and assistive technologies.

With these advancements, Phantom Neuro remains committed to revolutionizing neurotechnology, empowering individuals with enhanced mobility, and redefining the future of human-machine interaction.